一项回顾性队列研究：Wilson 病患者 SARS-CoV-2 疫苗接种状况及安全性分析。

A retrospective cohort study: vaccination status and safety analysis of SARS-CoV-2 vaccine in patients with Wilson's disease.

机构信息

Neurology Department, The First Affiliated Hospital, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China.

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China.

出版信息

Expert Rev Vaccines. 2023 Jan-Dec;22(1):1185-1195. doi: 10.1080/14760584.2023.2288630. Epub 2023 Dec 1.

DOI:10.1080/14760584.2023.2288630

PMID:38010939

Abstract

BACKGROUND

Wilson's disease (WD) is a rare hepatic and neurological disorder, which can dramatically worsen by traumatic injuries, surgeries, and infections. No studies have reported safety data of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in WD patients. We aimed to investigate the SARS-CoV-2 vaccination status and post-vaccination adverse events in WD patients.

METHODS

This is a multicenter, retrospective, observational study. We investigated the vaccination rates, the type of vaccine, subjective reasons for non-vaccination, and the adverse events following vaccination. Logistic regression analysis was used to assess the correlation between vaccination status and increased Unified Wilson's Disease Rating Scale (UWDRS) scores.

RESULTS

A total of 554 WD patients with a mean (SD) age of 25.3 (10.85) years were included in this study, of whom 336 (60.6%) were males and 218 (39.4%) were females. 368 (66.4%) patients received at least one dose of the SARS-CoV-2 vaccine.186 (33.6%) patients were unvaccinated. Logistic regression analysis showed that vaccination against SARS-CoV-2 was not significantly associated with increased UWDRS scores. The safety analysis demonstrated that 21.2% had post-vaccination adverse events.

CONCLUSIONS

In this study, vaccination against SARS-CoV-2 was safe in WD patients, providing evidence for the safety of vaccination in WD patients.

摘要

背景

Wilson 病（WD）是一种罕见的肝脏和神经系统疾病，在创伤、手术和感染后可能会急剧恶化。目前尚无研究报告 WD 患者接种严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗的安全性数据。我们旨在调查 WD 患者的 SARS-CoV-2 疫苗接种状况和接种后不良事件。

方法

这是一项多中心、回顾性、观察性研究。我们调查了疫苗接种率、疫苗类型、未接种疫苗的主观原因以及接种后不良事件。采用逻辑回归分析评估接种状况与统一 Wilson 病评定量表（UWDRS）评分增加之间的相关性。

结果

本研究共纳入 554 例 WD 患者，平均（SD）年龄为 25.3（10.85）岁，其中 336 例（60.6%）为男性，218 例（39.4%）为女性。368 例（66.4%）患者至少接种了 1 剂 SARS-CoV-2 疫苗。186 例（33.6%）患者未接种疫苗。逻辑回归分析表明，接种 SARS-CoV-2 疫苗与 UWDRS 评分增加无显著相关性。安全性分析显示，21.2%的患者出现接种后不良事件。